Big pharma pursues targeted expansion while trials in radiopharmaceuticals and immunotherapy highlight the breadth of innovation across cancer, …
Big pharma pursues targeted expansion while trials in radiopharmaceuticals and immunotherapy highlight the breadth of innovation across cancer, …
New pivotal trial milestones in multiple sclerosis and head and neck cancer, plus key collaboration and funding moves, …
MaaT Pharma advances its microbiome ecosystem therapies with new preclinical evidence showing enhanced patient immunotherapy responses.
MaaT Pharma strengthens financial position to advance its microbiome-based therapies, focusing on acute graft-versus-host disease and hemato-oncology indications.
March 2025 is marked by significant deal-making, promising clinical trial results, and innovations across small molecules, biologics, and …
India’s Sun Pharmaceutical Industries strengthens its immuno-oncology capabilities with acquisition of U.S.-based Checkpoint Therapeutics.
The biopharma sector sees soaring merger and acquisition activity in March 2025, with major deals advancing innovation in …
Investments in next-generation manufacturing facilities are unlocking scale, speed, and quality for cell and gene therapies, propelling North …
European regulatory reforms are accelerating approvals for novel rare disease treatments, attracting global investment and expanding patient access.
Record venture investment is driving new biotech companies in Australia to accelerate research, clinical development, and global partnerships.
Already a subscriber? Log in